Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice

Bibliographic Details
Main Authors:	Simone Oerlemans, M. Christine Bennink, Mark David Levin, Annemiek Broijl, Marjolein Van der Klift, Judith Van Deursen, Daphne Vogels, Lonneke V. Van de Poll-Franse, Pieter Sonneveld, Jan A. Hazelzet, Lidwine W. Tick
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000366

Similar Items

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
by: Christine Bennink, et al.
Published: (2023-06-01)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
by: M. Christine Bennink, et al.
Published: (2022-07-01)

Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial
by: Simone Oerlemans, et al.
Published: (2021-12-01)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
by: Ruth Wester, et al.
Published: (2022-02-01)

Plasmacytoma/multiple myeloma type posttransplant lymphoproliferative disorder
by: Theodora A.M. Claushuis, et al.
Published: (2022-05-01)

Comparing Survivors of Cancer in Population-Based Samples With Those in Online Cancer Communities: Cross-sectional Questionnaire Study
by: Mies C van Eenbergen, et al.
Published: (2022-03-01)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
by: Pim Mutsaers, et al.
Published: (2021-05-01)

Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
by: Marc S. Raab, et al.
Published: (2023-11-01)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
by: Ruth Wester, et al.
Published: (2020-08-01)

Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study
by: Jens Lehmann, et al.
Published: (2023-08-01)

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
by: Somayya Noori, et al.
Published: (2022-08-01)

B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA
by: M de Jong, et al.
Published: (2022-04-01)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
by: R. Wester, et al.
Published: (2023-05-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Long-term Outcomes in Patients With Multiple Myeloma
by: Silvia G.R. Verelst, et al.
Published: (2018-08-01)

Exploring Cancer Survivor Needs and Preferences for Communicating Personalized Cancer Statistics From Registry Data: Qualitative Multimethod Study
by: Ruben D Vromans, et al.
Published: (2021-10-01)

Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials
by: Edward Laane, et al.
Published: (2023-12-01)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context
by: Kaz Groen, et al.
Published: (2023-09-01)

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: Kaz Groen, et al.
Published: (2023-08-01)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
by: Meral Beksac, et al.
Published: (2023-08-01)

Differences in Internet Use and eHealth Needs of Adolescent and Young Adult Versus Older Cancer Patients; Results from the PROFILES Registry
by: Carla Vlooswijk, et al.
Published: (2021-12-01)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
by: Christie P.M. Verkleij, et al.
Published: (2023-05-01)

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: K. Groen, et al.
Published: (2023-05-01)

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: K. Groen, et al.
Published: (2022-06-01)

An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
by: de Jong, MME, et al.
Published: (2024)

P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Mattia D’agostino, et al.
Published: (2023-08-01)

Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma
by: Suzanne Murray, et al.
Published: (2018-04-01)

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
by: Shrivastava T, et al.
Published: (2023-06-01)

J.N.A. Groenendijk, De 'heeren' van Zaltbommel. Sociëteit 'De verdraagzaamheid' te Zaltbommel 1803-2003
by: M. van Deursen
Published: (2005-01-01)

D.Th. Kuiper, Predikant in Nederland (1800 tot heden)
by: M. van Deursen
Published: (1999-01-01)

E. van der Woude, K.I. Muller, Memorije van 't geen bij mijn tijt is voorgevallen. Met het opzienbarende verslag van haar reis naar de Wilde Kust 1676-1677, Muller, K. I., ed.
by: M. van Deursen
Published: (2002-01-01)

M. van der Burg, M. Bos-Boers, Vrouwen, Wageningen en de wereld. Wetenschap, studie en loopbaan, 1918-2003
by: M. van Deursen
Published: (2005-01-01)

J.W. Bloemink, D.J. de Vries, Verborgen verleden. Bouwhistorie in Nijmegen, Vries, D. J. de, e. a., ed.
by: M. van Deursen
Published: (2006-01-01)

H.A. Huussen jr., Hemmo Dijkema 1799-1853. Gronings agronoom en Ruslandreiziger
by: M. van Deursen
Published: (2004-01-01)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
by: Monique Minnema, et al.
Published: (2023-08-01)

Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study
by: Olga Husson, et al.
Published: (2021-05-01)

Incidence of Extramedullary Myeloma in Multiple Myeloma Patients
by: Sinan Demircioğlu, et al.
Published: (2019-07-01)

COVID-19 AND MYELOMA
by: H Ludwig, et al.
Published: (2022-04-01)

Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and sustainable metastatic breast cancer care is now
by: K.M. de Ligt, et al.
Published: (2024-04-01)

Specialist versus Primary Care Prostate Cancer Follow-Up: A Process Evaluation of a Randomized Controlled Trial
by: Barbara M. Wollersheim, et al.
Published: (2022-06-01)